Effect of Verapamil on Blood Glucose in Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Cardiovascular Drugs and Therapy · 2026
DOI: 10.1007/s10557-025-07683-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Drugs and Therapy, 2026. Verfasst von Shiqi Tu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, Hunan, 410011, PR China. Hauptthemen laut MEDLINE: Verapamil, Diabetes Mellitus, Type 2, Blood Glucose, Calcium Channel Blockers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: the Natural Science Foundation of Changsha, the Hunan Administration of Traditional Chinese Medicine, the Scientific Research Program of Hunan Provincial Health Commission.
Themen: Diabetes mellitus
Abstract (Originalsprache)
PURPOSE: Verapamil, an L-type calcium channel blocker treating hypertension, arrhythmia, and other cardiovascular diseases, has emerged as a potential drug for lowering blood glucose by regulating cellular calcium homeostasis and affecting expression of apoptosis-related proteins in pancreatic β-cells. However, this promising effect must be weighed against potential risks, including cardiovascular adverse effects of this drug. METHODS: We conducted a systematic review and meta-analysis and included randomized controlled trials (RCTs) assessing verapamil in individuals with type 1 or type 2 diabetes. The primary outcomes were glycated hemoglobin (HbA1c) and serum glucose concentration. The secondary outcomes were area under the curve (AUC) values for C-peptide level, body weight, changes in HbA1c and blood glucose concentration pre- and post-intervention, and adverse drug reactions. RESULTS: A total of eight RCTs involving 1100 patients were included in the analysis. Meta-analysis showed that verapamil effectively lowered blood glucose levels (weighted mean difference [WMD] -6.38, 95% CI -12.52, -0.25 mg/dL, P = 0.04; 6 trials), decreased HbA1c (WMD -0.45, 95% CI -0.66, -0.23%, P < 0.001; 7 trials), and increased C-peptide AUC (WMD 0.27, 95% CI 0.21, 0.32 pmol/mL, P < 0.0001; 2 trials) in patients with both type 1 and type 2 diabetes, without significant trial-related adverse events (OR 1.33, 95% CI 0.85, 2.09, P = 0.21). CONCLUSION: The adjunctive use of verapamil to standard hypoglycemic therapy is a safe and effective means of improving glycemic control in diabetic patients. However, the limited scale of RCTs and heterogeneity of basic glucose-lowering regimens across studies might constrain generalizability of these findings. Future high-quality research is warranted to further elucidate the role of verapamil in diabetes management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, Hunan, 410011, PR China.
- Institute of Clinical Pharmacy, Central South University, Changsha, 410011, PR China.
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
- Department of Pharmacy, Hospital of Chengdu Office of People'S Government of Tibetan Autonomous Region, Chengdu, 610000, China.
- Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, PR China.
- Department of Pharmacy, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, Hunan, 410011, PR China. 13526278113@163.com.
ORCID-Profile: Qiong Lu
Förderung
- the Natural Science Foundation of Changsha
- the Hunan Administration of Traditional Chinese Medicine
- the Scientific Research Program of Hunan Provincial Health Commission
- Natural Science Foundation of Hunan Province
- Hunan Innovative Province Construction Special Project
- Hunan Provincial Development and Reform Commission of Innovative Research Program
- the Hunan Provincial Department of Finance Gra
- the China National Key R&D Program
Zitieren
APA
Tu, S., Zhang, R., Zheng, Q., Wang, J., Chen, Y., Li, X., He, J., Zhou, Z., & Lu, Q. (2026). Effect of Verapamil on Blood Glucose in Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-025-07683-4
Vancouver
Tu S, Zhang R, Zheng Q, Wang J, Chen Y, Li X, et al. Effect of Verapamil on Blood Glucose in Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy. 2026. doi:10.1007/s10557-025-07683-4
BibTeX
@article{Tu2026,
author = {Tu, Shiqi and Zhang, Ruiqi and Zheng, Qiyue and Wang, Jiaojiao and Chen, Yun and Li, Xiaosi and He, Jieyu and Zhou, Zhaokai and Lu, Qiong},
title = {Effect of Verapamil on Blood Glucose in Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis},
journal = {Cardiovascular Drugs and Therapy},
year = {2026},
doi = {10.1007/s10557-025-07683-4}
}
EUVIMED